Advertisement

These 2 Biotech Stocks Are Up 1,000% This Year

These 2 Biotech Stocks Are Up 1,000% This Year

With all of the recent news around a new treatment for Alzheimer's disease (AD), the huge gains by smaller biotechs developing treatments can get lost. Now that the Food and Drug Administration has approved Biogen's (NASDAQ: BIIB) Aduhelm despite its mixed results, it theoretically made it much easier for new treatments to get the green light. Unlike most AD drugs, Annovis Bio's ANVS401 isn't designed to get rid of amyloid in the brain.